Palexia Retard

Active Ingredient:: Tapentadol Hydrochloride
Origin:: EU

Palexia Retard (Tapentadol Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as an extended‑release tablet for oral use. It is indicated for the management of moderate to severe acute pain, chronic pain and cancer‑related pain in adult patients.
GNH India supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Grünenthal Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Palexia Retard is an opioid analgesic used in the management of pain conditions across several clinical pathways.

Acute pain: Provides rapid relief of moderate to severe pain following surgery or injury.
Chronic non‑cancer pain: Helps control persistent pain that has not responded adequately to non‑opioid therapies.
Cancer pain: Alleviates moderate to severe pain associated with malignant disease and its treatment.

How It Works

Tapentadol Hydrochloride acts as a dual‑action agent. It binds to mu‑opioid receptors, producing opioid‑mediated analgesia, while simultaneously inhibiting the reuptake of norepinephrine, which enhances descending pain‑modulating pathways. This combined mechanism results in effective reduction of pain signals at both spinal and supraspinal levels.

Side Effects

Adverse reactions to Palexia Retard may vary in frequency and severity.

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel movements.
Dizziness: feeling light‑headed or unsteady.
Somnolence: increased sleepiness.
Headache: mild to moderate head pain.
Dry mouth: reduced salivation.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing.
Severe hypotension: marked drop in blood pressure.
Seizures: convulsive episodes.
Opioid use disorder: risk of dependence or addiction.
Anaphylaxis: severe allergic reaction with rash, swelling or airway compromise.

Precautions & Warnings

When prescribing Palexia Retard, clinicians should consider several safety aspects.

Assess pain severity and opioid tolerance before initiating therapy.
Monitor for signs of respiratory depression, especially during dose titration.
Evaluate hepatic and renal function, adjusting dose if impairment is present.
Avoid concomitant use with other central nervous system depressants when possible.
Educate patients on proper use, risks of dependence and safe storage.
Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Avoid Interactions

Palexia Retard can interact with a range of medicines; awareness of interaction severity guides clinical management.

Major Interactions (Avoid)

CNS depressants: combined use may cause profound sedation or respiratory depression.
MAO inhibitors: may precipitate hypertensive crisis or serotonin syndrome.
CYP2D6 inhibitors: can increase tapentadol plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

Serotonergic agents (SSRIs, SNRIs): may increase risk of serotonin syndrome.
Benzodiazepines: additive sedative effects require dose adjustment.
Antihistamines: may enhance central nervous system depression.
Diuretics: can potentiate hypotensive effects.

Frequently Asked Questions

Palexia Retard is an extended‑release formulation of tapentadol hydrochloride indicated for the treatment of moderate to severe acute pain, chronic non‑cancer pain and cancer‑related pain in adult patients when other analgesics are insufficient.

Tapentadol provides analgesia through two mechanisms: it activates mu‑opioid receptors to reduce pain signaling and blocks the reuptake of norepinephrine, which strengthens the body’s own descending pain‑inhibition pathways. The combined effect lowers the perception of pain at spinal and brain levels.

The dosage of Palexia Retard is individualized; a qualified prescriber determines the appropriate strength and dosing schedule based on the patient’s pain severity, prior opioid exposure and overall health status.

Safety data for tapentadol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Palexia Retard combines opioid receptor activation with norepinephrine reuptake inhibition, which may provide effective analgesia at lower opioid doses compared with pure mu‑opioid agonists. This dual mechanism can result in a different side‑effect profile, though individual response varies.

Store Palexia Retard tablets at ambient temperature, below 25 °C, in the original container. Protect them from moisture, direct sunlight and excessive heat to maintain potency.

Palexia Retard is taken orally as a whole tablet. It should be swallowed with water and not crushed, chewed or split, to preserve the extended‑release characteristics.

The most serious risks include respiratory depression, severe hypotension, seizures, opioid dependence and rare allergic reactions such as anaphylaxis. Patients should be monitored closely, especially during treatment initiation and dose adjustments.

Palexia Retard is contraindicated in individuals with known hypersensitivity to tapentadol or any tablet components, those who have experienced severe respiratory depression from opioids, and patients taking MAO‑inhibitors within 14 days.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.